| The following article features coverage from the 2018 Gastrointestinal Cancers Symposium. Click here to read more of Cancer Therapy Advisor‘s conference coverage. |
Long-term data from an ongoing study showed that nivolumab prolongs overall survival (OS) and continues to maintain clinically meaningful durable responses among patients with DNA mismatch repair–deficient/microsatellite instability–high (dMMR/MSI-H) metastatic colorectal cancer (mCRC), according to research being presented at the 2018 Gastrointestinal Cancers Symposium in California.1
For the open-label, phase 2 CheckMate-142 trial (ClinicalTrials.gov Identifier: NCT02060188), researchers treated 74 patients with dMMR/MSI-H mCRC with nivolumab 3 mg/kg every 2 weeks. Eligible patients had progressed or were intolerant of at least 1 previous line of treatment, including a fluoropyrimidine, oxaliplatin, and irinotecan. Results from a previous follow-up showed that the overall response rate (ORR) was 32% and the disease control rate was 64% among patients treated with nivolumab.
Continue Reading
The median follow-up of the current study was 21 months. ORR was 34%, and the complete response (CR) rate improved from 3% to 9%. Patients treated with 2 or fewer chemotherapy regimens had numerically higher responses compared with patients who were previously treated with fluoropyrimidine, oxaliplatin, and irinotecan.
Grade 3 to 4 treatment-related adverse events (TRAEs) were observed in 20% of patients; 10% of patients who received 2 or fewer treatment lines reported TRAEs vs 25% of patients who received chemotherapy with fluoropyrimidine, oxaliplatin, and irinotecan.
Read more of Cancer Therapy Advisor‘s coverage of the 2018 Gastrointestinal Cancers Symposium by visiting the conference page.
Reference
- Overman MJ, Bergamo F, McDermott RS, et al. Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): long-term survival according to prior line of treatment from CheckMate-142. Oral presentation at: 2018 Gastrointestinal Cancers Symposium; January 18-20, 2018; San Francisco, CA.
